Skip to content

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Dermatitis Atopic

Primary Objectives:

* To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
* To evaluate the time-course of AD and selected atopic comorbidities.

Secondary Objectives:

* To characterize disease burden and unmet need.
* To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching).
* To document the real-world effectiveness and safety of treatments.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    0 to 11

Critères de participation

Inclusion criteria:

* Patients with moderate to severe AD, according to the Investigator's assessment;
* Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.

Exclusion criteria:

* Concurrent participation in an interventional clinical trial which modifies patient care.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Lieu de l'étude

Investigational Site Number : 1240004
Investigational Site Number : 1240004
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Investigational Site Number : 1240001
Investigational Site Number : 1240001
Markham, Ontario
Canada

Contactez l'équipe d'étude

Investigational Site Number : 1240010
Investigational Site Number : 1240010
Halifax, Nova Scotia
Canada

Contactez l'équipe d'étude

Investigational Site Number : 1240009
Investigational Site Number : 1240009
Regina, Saskatchewan
Canada

Contactez l'équipe d'étude

Investigational Site Number : 1240005
Investigational Site Number : 1240005
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Investigational Site Number : 1240006
Investigational Site Number : 1240006
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Investigational Site Number : 1240007
Investigational Site Number : 1240007
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Investigational Site Number : 1240008
Investigational Site Number : 1240008
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Étude parrainée par
Sanofi
Participants recherchés
Plus d'informations
ID de l'étude: NCT03687359